Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial. (linkinghub.elsevier.com)

Authors: Xiong A … Zhou C Journal: The Lancet Published: 2026-05-29 DOI: https://doi.org/10.1016/S0140-6736(26)00968-2